IoB Seminar Series: Dr Gianni Dal Negro, Complex in Vitro models: challenges and expectations to fill the gaps
Date: 30 November 2016 Time: 15:00 - 16:00
The high attrition rate that the pharmaceutical industry is still facing indicates that the current tools for conducting our research too often fail in predicting the outcome in patients. Although considerable advances have been made in understanding differences and similarities between patients and pre- clinical animal species as models for human patho-physiology, in some cases we still fail in predicting results obtained in humans in particular when addressing challenges relating to human efficacy and toxicity. On the other hand, most of cell culture models developed as surrogates of tissues and organs commonly fail to maintain differentiation and expression of tissue-specific functions. In addition, these in vitro systems lack of integrated physiology, making it challenging to model complex patho- physiological processes involving different tissues and organs.
In the pharmaceutical research, the urgent need for new solutions to bridge the gap between pre- clinical and clinical research is a driver in seeking innovative technologies and approaches that secure a discrete translational line of sight to patients.
In GSK, a new enterprise modeling approach for improving clinical translation has been developed. This approach entails a thorough and critical evaluation of new in vivo and in vitro models according to a GSK-wide harmonized scientific due diligence process. This approach also entails a retrospective evaluation of models against clinical readouts.
In this presentation, the challenges in the identification of new human-relevant pre-clinical models are presented. Some examples of technologies under scientific evaluation will be also provided.
|Location:||PP1 Lecture Theatre, People’s Palace, Mile End|
|Contact:||Dr Gianni Dal Negro|